A double-blind, randomized study of two different dosage regimens of intravenous dolasetron in patients receiving high-dose cisplatin chemotherapy

Cancer Investigation

Volumn 15, Issue 4, 1997, Pages 304-310

  Kasimis, Basil S ^a   Tapazoglou, Efstathios ^b   Schulman, Phillip ^c   Stewart, William H ^d   Hahne, William F ^d   Cramer, Michael B ^d  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b ST JOHN HOSPITAL AND MEDICAL CENTER   (United States)

^c NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^d SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOLASETRON MESILATE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; METHOTREXATE; VINBLASTINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG CANCER; MALE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOMITING;

EID: 0030842842     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357909709039730     Document Type: Article

References (24)

1. Gralla RJ: Current issues in the management of nausea and vomiting. Ann Oncol 4(Suppl 3):S3-7, 1993.
2. Laszlo J, Lucas VS Jr: Emesis as a critical problem in chemotherapy. N Engl J Med 305:948-949, 1981.
3. 3 antagonists. Support Care Cancer 2:286-292, 1994.
4. Del Favero A, Roila F, Tonato M: Reducing chemotherapy-induced nausea and vomiting. Current perspectives and future possibilities. Drug Safety 9:410-428, 1993.
5. Grunberg SM, Hesketh PJ: Control of chemotherapy-induced emesis. N Engl J Med 329:1790-1796, 1993.
6. 3 receptor antagonists. An overview of their present status and future potential in cancer therapy-induced emesis. Drugs 42:551-568, 1991.
7. Fozard JR: MDL 72222: A potent and highly selective antagonist at neuronal 5-hydroxytryptamine receptors. Naunyn-Schmiedeberg's Arch Pharmacol 326:36-44, 1984.
8. 3 receptors. Drug Dev Res 28:87-93, 1993.
9. Miner WD, Sanger GJ: Inhibition of cisplatin induced vomiting by selective 5-hydroxytryptamine M-receptor antagonism. Br J Pharmacol 88:497-499, 1986.
10. Boxenbaum H, Gillespie T, Heck K, et al: Human dolasetron pharmacokinetics. I. Disposition following single-dose intravenous administration to normal male subjects. Biopharm Drug Dispos 13:693-701, 1992.
11. 3 antagonist, in cancer patients treated with cisplatin. Am J Clin Oncol 17:97-102, 1994.
12. 3-receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. Ann Oncol 4:481-484, 1993.
13. Kris MG, Grunberg SM, Gralla RJ, et al: Dose-ranging evaluation of the serotonin antagonist dolasetron mesylate in patients receiving high-dose cisplatin. J Clin Oncol 12:1045-1049, 1994.
14. Merrouche Y, Catimel G, Rebattu P, et al: A phase I antiemetic study of MDL 73,147EF, a novel 5-hydroxytryptamine antagonist in cancer patients receiving emetogenic chemotherapy. Ann Oncol 5:549-551, 1994.
15. Lee CR, Plosker GL, McTavish D: Tropisetron: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as an antiemetic. Drugs 46:925-943, 1993.
16. Milne RJ, Heel RC: Ondansetron. Therapeutic use as an antiemetic. Drugs 41:574-595, 1991.
17. Plosker GL, Goa KL: Granisetron. A review of its pharmacological properties and therapeutic use as an antiemetic. Drugs 42:805-824, 1991.
18. Heck K, Holmes GB, Adams MA, et al: A double-blind, placebo-controlled, dose-rising tolerance study of intravenous MDL 73,147EF in normal volunteers. Clin Pharmacol Ther 51:186, 1992 (abstract).
19. Hunt TL, Cramer M, Shah A, et al: A double-blind, placebo-controlled, dose-ranging safety evaluation of single-dose intravenous dolasetron in healthy male volunteers. J Clin Pharmacol 35:705-712, 1995.
20. 3) receptor antagonist (MDL 73,147EF) in patients receiving high dose cisplatin chemotherapy. Proc Am Soc Clin Oncol 11:395, 1992 (abstract).
21. Kasimis B, Tapazoglou E, Schulman P, et al: A double-blind, randomized study of two different dose regimens of intravenous (IV) dolasetron (DOL) in patients (PTS) receiving high dose cisplatin (CDDP) chemotherapy. Proc Am Soc Clin Oncol 13:446, 1994 (abstract).
22. 3 antagonist in 41 patients requiring intravenous chemotherapy. Proc Am Soc Clin Oncol 10:337, 1991 (abstract).
23. Plezia P, Modiano M, Alberts D, et al: A double-blind, randomized, parallel study of two doses of intravenous (IV) MDL 73,147EF in patients (PTS) receiving high dose cisplatin (CDDP)-containing chemotherapy (CT). Proc Am Soc Clin Oncol 11:407, 1992 (abstract).
24. Hunt TL, Cramer M, Christy-Bittel J, et al: Multiple dose, placebo-controlled phase I study of oral dolasetron. Pharmacotherapy (in press).